Research progress on the P2X7 receptor in liver injury and hepatocellular carcinoma

Chem Biol Drug Des. 2023 Mar;101(3):794-808. doi: 10.1111/cbdd.14182. Epub 2022 Nov 29.

Abstract

Purinergic ligand-gated ion channel 7 receptor (P2X7 receptor) is an adenosine triphosphate (ATP)-gated ion channel that is widely distributed on the surfaces of immune cells and tissues such as those in the liver, kidney, lung, intestine, and nervous system. Hepatocellular carcinoma (HCC) is one of the most common malignancies with increasing incidence and mortality. Although many treatments for liver cancer have been studied, the prognosis for liver cancer is still very poor. Therefore, new liver cancer treatments are urgently needed. P2X7 receptor activation can secrete proinflammatory factors through the P2X7 receptor-NLRP3 signaling pathway, thereby affecting the progression of liver injury. The P2X7 receptor may be a target for growth inhibition of HCC cells and may affect the invasion and migration of HCC cells through the PI3K/AKT and AMPK signaling pathways. In recent years, P2X7 receptor antagonists or inhibitors have attracted widespread attention as therapeutic targets for hepatocellular carcinoma and liver injury. Therefore, this review covers the basic concepts of the P2X7 receptor and role of the P2X7 receptor in liver cancer and liver injury, providing new potential therapeutic targets for hepatocellular carcinoma and liver injury.

Keywords: ATP; P2X7 receptor; liver cancer; liver injury.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Carcinoma, Hepatocellular*
  • Humans
  • Liver Neoplasms* / pathology
  • Phosphatidylinositol 3-Kinases / metabolism
  • Receptors, Purinergic P2X7

Substances

  • Receptors, Purinergic P2X7
  • Phosphatidylinositol 3-Kinases
  • Adenosine Triphosphate